AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17302061
Drug: TCM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM treatment beginning with Fei (SLE I formula in active stage or SLE II formula in silent period)
Trial: 9782602
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (3 x 400 mg RRR‐alpha‐Tocopherolacetat/d)
Trial: 26083656
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (325 mg three times daily for 8 weeks)
Trial: 26083656
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg every 2 weeks, total 1 g)
Trial: 23016924
Drug: ABT-288 single
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 single doses (0.1, 0.3, 1, 3, 10, 20, and 40 mg)
Trial: 23016924
Drug: ABT-288 multiple
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 multiple doses (0.5, 1.5, 3, and 6 mg once-daily for 14 days in young adults)
Trial: 23016924
Drug: ABT-288 multiple
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 multiple doses (0.5, 1.5, 3, and 5 mg once-daily for 12 days in elderly subjects)
Trial: 23016924
Drug: ABT-288 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-288 (5 mg single dose) with food
Trial: 21118746
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of oral risperidone 2 mg
Trial: 21118746
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of oral risperidone 2 mg
Trial: 18200463
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose diathermy technique
Trial: 12811310
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 7 days
Trial: 12811310
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily for 7 days
Trial: 8923017
Drug: Various combinations
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combinations of vitamins and minerals at supranutritional doses
Trial: 6391784
Drug: Droperidol 2.5
RxNorm normalized name: droperidol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 2.5 mg (for cisplatin >= 100 mg/sq m) or 1.25 mg (for subsequent doses < 100 mg/sq m)
Trial: 6391784
Drug: Metoclopramide 2
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 2 mg/kg (for cisplatin >= 100 mg/sq m) or 1 mg/kg (for subsequent doses < 100 mg/sq m)
Trial: 6391784
Drug: Prochlorperazine 5
RxNorm normalized name: prochlorperazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 5 mg (for both dosages of cisplatin)
Trial: 27008285
Drug: Progressive relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive relaxation therapy
Trial: 24170102
Drug: Tetracosactide (ACTH1‐24)
RxNorm normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracosactide (ACTH1‐24) therapy
Trial: 22186968
Drug: Prehospital loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital loading dose of 600 mg clopidogrel
Trial: 22186968
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (clopidogrel administered after diagnostic angiogram)
Trial: 22186968
Drug: Prehospital loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital loading dose of 600 mg clopidogrel (treated patients)
Trial: 22186968
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (treated patients)
Trial: 20107434
Drug: Varenicline 0.5
RxNorm normalized name: varenicline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 0.5 mg b.i.d.
Trial: 22080588
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg b.i.d.
Trial: 20107434
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg b.i.d. (Male)
Trial: 20107434
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg b.i.d. (Female)
Trial: 14551147
Drug: Progestagen-only preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestagen-only preparations
Trial: 11216928
Drug: Second-line protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line protease inhibitor regimen (specific PIs include indinavir and nelfinavir)
Trial: 11216928
Drug: Second-line protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line protease inhibitor regimen with added nucleosides
Trial: 9522133
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral 3-in-1 block with 0.5% bupivacaine 2 mg kg-1
Trial: 8026196
Drug: D‐beta‐hydroxybutyrate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐beta‐hydroxybutyrate infusion
Trial: 2644580
Drug: RS-86 (cholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-86 (cholinergic agonist)
Trial: 31521496
Drug: Lavage Treatment
RxNorm normalized name: Peritoneal Lavage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavage Treatment (LT) group
Trial: 25548861
Drug: 3-week sensory
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week sensory cueing treatment
Trial: 25548861
Drug: 3-week sham
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week sham treatment
Trial: 22824168
Drug: L-Carnitine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (4 g) for 12 weeks
Trial: 18154124
Drug: Cisplatin 6
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 6 mg/m2 intravenously, daily; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Trial: 18154124
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m2, weekly; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Trial: 18154124
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2, once in 3 weeks; Radiation therapy: 2 Gy per fraction, 5 times a week, up to 68-70 Gy
Trial: 15131005
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitor (ramipril)
Trial: 15131005
Drug: AT1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AT1 antagonist (valsartan)
Trial: 464673
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose with an amino acid solution containing 22% BCAAs
Trial: 464673
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose with an amino acid solution containing 35% BCAAs
Trial: 464673
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose with an amino acid solution containing 100% BCAAs
Trial: 31075393
Drug: THC (dronabinol;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (dronabinol; 5-50 mg, dose individually tailored)
Trial: 27402452
Drug: Automated low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated low glucose insulin suspension system (intervention nights)
Trial: 27402452
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of pump suspension
Trial: 19770386
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m(2) twice weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm A)
Trial: 19770386
Drug: Bortezomib 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.6 mg/m(2) weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm B)
Trial: 19770386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied as single-agent rituximab in ongoing phase III study)
Trial: 17803818
Drug: ProAlgaZyme (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProAlgaZyme (4 fl oz daily)
Trial: 15249319
Drug: Paracetamol 4
RxNorm normalized name: Paracetamol 48.2 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4 g/day (n = 405)
Trial: 15249319
Drug: Paracetamol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (n = 63) in chronic mechanical knee pain subgroup
Trial: 10325993
Drug: Hs +
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hs + Ad group (Hartmann's solution containing 0.5 ml of 1:1000 adrenaline per 500 ml)
Trial: 10325993
Drug: Hs group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hs group (Hartmann's solution alone)
Trial: 7704169
Drug: Serotype 1
RxNorm normalized name: Aspergillus fumigatus serotype 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotype 1 vaccine
Trial: 504973
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (s.c.) injected twice a day
Trial: 504973
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (i.v.) given by continuous perfusion
Trial: 30734016
Drug: Chemotherapy administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy administration
Trial: 26062880
Drug: Triple treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple treatment (lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide)
Trial: 26062880
Drug: Dual treatment
RxNorm normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual treatment (lopinavir-ritonavir plus lamivudine)
Trial: 24521629
Drug: Fenofibrate 160
RxNorm normalized name: fenofibrate 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 160 mg/day
Trial: 21248328
Drug: Limit feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limit feeding diets containing DDGS at levels of 65 or 55 g/hen per day during the molt period
Trial: 17085151
Drug: Aprepitant 160
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 160 mg once daily for 8 weeks
Trial: 2004322
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (external irradiation to a dose of 5000 cGy in 5 weeks)
Trial: 20969601
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days
Trial: 20969601
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 0.5 mg twice daily
Trial: 20969601
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 1.0 mg twice daily
Trial: 19004202
Drug: Drug group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug group (routine medication)
Trial: 19004202
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (including MNEFMSA, affected-channel, and drug)
Trial: 8269208
Drug: m7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: m7E3 Fab (0.15 to 0.35 mg/kg)
Trial: 8269208
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg orally per day)
Trial: 3518384
Drug: Hydralazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (mean titrated dose 96 +/- 9 mg, mean treatment dose 63 +/- 21 mg administered 3 times daily)
Trial: 30200078
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly (ETN50)
Trial: 27441577
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic (cefazolin 2 g 30 min before surgery with repetition at 1 g every 3 h during surgery)
Trial: 27441577
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (Control)
Trial: 23087488
Drug: Perphenazine (typical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (typical antipsychotic medication)
Trial: 23087488
Drug: Newer atypical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer atypical antipsychotics
Trial: 15356967
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate (CC)
Trial: 12697116
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng injection
Trial: 12697116
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy without Shenqi Fuzheng injection
Trial: 9162613
Drug: Troglitazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (400 mg day(‐1))
Trial: 30093681
Drug: Tamibarotene (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamibarotene (6 mg/m2 daily for 14 days every 3 months for 2 years)
Trial: 30093681
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) (45 mg/m2 daily for 14 days every 3 months for 2 years)
Trial: 30347030
Drug: L‐CRA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐CRA plus monthly injections of intravitreal ranibizumab, 0.5 mg (combination group; n = 29)
Trial: 30347030
Drug: Ranibizumab alone
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab alone (sham procedure plus monthly injections of intravitreal ranibizumab, 0.5 mg; n = 29)
Trial: 27603152
Drug: HOME program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOME program (enhanced occupational therapy discharge planning intervention with pre- and postdischarge home visits)
Trial: 23272061
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injections (Control)
Trial: 20386343
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral estrogen (1 mg) combined with drospirenone (2 mg) for 2 years
Trial: 12645863
Drug: Danazol treatment
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol treatment for 12 weeks
Trial: 8621010
Drug: Indomethacin (INDO)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (INDO) 50 mg q.i.d.
Trial: 31812510
Drug: Belapectin 2
RxNorm normalized name: Selamectin
DrugBank: Selamectin (DB11459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belapectin 2 mg/kg
Trial: 31812510
Drug: Belapectin 8
RxNorm normalized name: Selamectin
DrugBank: Selamectin (DB11459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belapectin 8 mg/kg
Trial: 31812510
Drug: Belapectin 2
RxNorm normalized name: Selamectin
DrugBank: Selamectin (DB11459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belapectin 2 mg/kg (subgroup without esophageal varices)
Trial: 27834984
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone 0.1 mg kg⁻¹
Trial: 27834984
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.1 mL kg⁻¹
Trial: 24747504
Drug: Memantine hydrochloride
RxNorm normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memantine hydrochloride (Memary) at a dose of 20 mg/day
Trial: 20970380
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate with whole brain radiotherapy (n=154)
Trial: 20970380
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate without whole brain radiotherapy (n=164)
Trial: 20970380
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate with whole brain radiotherapy
Trial: 20970380
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate without whole brain radiotherapy
Trial: 16030104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of selenium and vitamin E supplementation for 3 to 6 weeks before prostatectomy
Trial: 12161049
Drug: Transdermal hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormonal replacement therapy system
Trial: 12349828
Drug: Ad(GV)CFTR.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)CFTR.10 administered to airways of individuals with cystic fibrosis (3 x 10(7) to 2 x 10(10) particle units)
Trial: 12349828
Drug: Ad(GV)VEGF121.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)VEGF121.10 administered to myocardium of individuals with coronary artery disease (4 x 10(8) to 4 x 10(10) particle units)
Trial: 12349828
Drug: Ad(GV)VEGF121.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)VEGF121.10 administered to lower extremity muscles of individuals with peripheral vascular disease (4 x 10(8) to 4 x 10(9.5) particle units)
Trial: 12349828
Drug: Ad(GV)CD.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)CD.10 administered to skin of normal individuals (7 x 10(7) to 7 x 10(9) particle units)
Trial: 12349828
Drug: Ad(GV)CD.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)CD.10 administered to airways of normal individuals (7 x 10(8) to 7 x 10(10) particle units)
Trial: 12349828
Drug: Ad(GV)CD.10 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad(GV)CD.10 administered to liver metastasis of individuals with colon carcinoma (4 x 10(8) to 4 x 10(9) particle units)
Trial: 12349828
Drug: Control individuals
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control individuals who had chest surgery and bronchoscopy, but no vector administration
Trial: 2136974
Drug: Anaritide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaritide (all doses except the highest 0.300 microgram/kg/min)
Trial: 350491
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg bufexamac
Trial: 29436942
Drug: 6‐mm‐long implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mm‐long implants
Trial: 29436942
Drug: Normal‐length implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal‐length implants (10 mm)
Trial: 26902546
Drug: DTwP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP vaccine first
Trial: 26902546
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine first
Trial: 18337284
Drug: Amoxicillin 1500
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1500 mg QD (or 750 mg if bodyweight ≤30 kg)
Trial: 18337284
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 500 mg BID (or 250 mg if bodyweight ≤20 kg)
Trial: 12846450
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leptin (rL) 10 mg once daily
Trial: 12846450
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human leptin (rL) 10 mg twice daily